DAPA/MET XR + DAPA + MET XR
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Prevention in Women After GDM Who Are at High-risk
Conditions
Diabetes Prevention in Women After GDM Who Are at High-risk
Trial Timeline
Sep 22, 2015 → Mar 13, 2019
NCT ID
NCT02338193About DAPA/MET XR + DAPA + MET XR
DAPA/MET XR + DAPA + MET XR is a phase 3 stage product being developed by AstraZeneca for Diabetes Prevention in Women After GDM Who Are at High-risk. The current trial status is completed. This product is registered under clinical trial identifier NCT02338193. Target conditions include Diabetes Prevention in Women After GDM Who Are at High-risk.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02338193 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Prevention in Women After GDM Who Are at High-risk